Pyrantel PamoateCAS# 22204-24-6 |
- BS-181
Catalog No.:BCC1439
CAS No.:1092443-52-1
- CDK inhibitor II
Catalog No.:BCC1464
CAS No.:1269815-17-9
- CGP60474
Catalog No.:BCC1474
CAS No.:164658-13-3
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- AT7519
Catalog No.:BCC2541
CAS No.:844442-38-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 22204-24-6 | SDF | Download SDF |
| PubChem ID | 5281033 | Appearance | Powder |
| Formula | C34H30N2O6S | M.Wt | 594.692 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 35 mg/mL (58.86 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;1-methyl-2-[(E)-2-thiophen-2-ylethenyl]-5,6-dihydro-4H-pyrimidine | ||
| SMILES | CN1CCCN=C1C=CC2=CC=CS2.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O | ||
| Standard InChIKey | AQXXZDYPVDOQEE-MXDQRGINSA-N | ||
| Standard InChI | InChI=1S/C23H16O6.C11H14N2S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-6,9H,3,7-8H2,1H3/b;6-5+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Pyrantel Pamoate Dilution Calculator
Pyrantel Pamoate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6815 mL | 8.4077 mL | 16.8154 mL | 33.6309 mL | 42.0386 mL |
| 5 mM | 0.3363 mL | 1.6815 mL | 3.3631 mL | 6.7262 mL | 8.4077 mL |
| 10 mM | 0.1682 mL | 0.8408 mL | 1.6815 mL | 3.3631 mL | 4.2039 mL |
| 50 mM | 0.0336 mL | 0.1682 mL | 0.3363 mL | 0.6726 mL | 0.8408 mL |
| 100 mM | 0.0168 mL | 0.0841 mL | 0.1682 mL | 0.3363 mL | 0.4204 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pyrantel Pamoate
- Lyn peptide inhibitor
Catalog No.:BCC5895
CAS No.:222018-18-0
- L-Canavanine sulfate
Catalog No.:BCC6746
CAS No.:2219-31-0
- Macrocarpal N
Catalog No.:BCN5811
CAS No.:221899-21-4
- Zotarolimus(ABT-578)
Catalog No.:BCC5481
CAS No.:221877-54-9
- Methylswertianin
Catalog No.:BCN8505
CAS No.:22172-17-4
- Conocarpan
Catalog No.:BCN5053
CAS No.:221666-27-9
- OBAA
Catalog No.:BCC6716
CAS No.:221632-26-4
- L-Menthol
Catalog No.:BCN4971
CAS No.:2216-51-5
- Boron tributoxide
Catalog No.:BCN8281
CAS No.:688-74-4
- 2,6-Dimethoxy-1-acetonylquinol
Catalog No.:BCN5052
CAS No.:2215-96-5
- 1-Benzyl-1H-indazol-3-ol
Catalog No.:BCC8458
CAS No.:2215-63-6
- Stigmastane-3,6-dione
Catalog No.:BCN5051
CAS No.:22149-69-5
- Naproxen
Catalog No.:BCC9091
CAS No.:22204-53-1
- Dihydroseselin
Catalog No.:BCN8258
CAS No.:2221-66-1
- Dehydroglaucine
Catalog No.:BCN2548
CAS No.:22212-26-6
- Cucurbitacin I
Catalog No.:BCC2439
CAS No.:2222-07-3
- Thalrugosaminine
Catalog No.:BCN7745
CAS No.:22226-73-9
- Fern-7-en-19-one
Catalog No.:BCN6443
CAS No.:222294-61-3
- 7-Amino-3-methyl-3-cephem-4-carboxylic acid
Catalog No.:BCC8776
CAS No.:22252-43-3
- Ipratropium Bromide
Catalog No.:BCC3795
CAS No.:22254-24-6
- Methyl 6-hydroxyangolensate
Catalog No.:BCN5054
CAS No.:22255-07-8
- alpha-Amyrin palmitate
Catalog No.:BCN5055
CAS No.:22255-10-3
- Guaijaverin
Catalog No.:BCN5056
CAS No.:22255-13-6
- Trimethoxystilbene
Catalog No.:BCN6762
CAS No.:22255-22-7
[Albendazole in Japanese juvenile with enterobiasis in whom pyrantel pamoate is not effective].[Pubmed:22117382]
Kansenshogaku Zasshi. 2011 Sep;85(5):520-2.
A 18-year-old Japanese woman seen as an outpatient for refractory enterobiasis had been treated with Pyrantel Pamoate over 40 times since the age of 11. She washed her hands and cleaned house frequently, and all family members took Pyrantel Pamoate, but Enterobius vermicularis eggs remained. She was orally administered 400 mg of albendazole 3 times in clinic visits, after which eggs have not been seen for 1 year. Pyrantel Pamoate is used widely against enterobiasis in Japan. Our case shows albendazole to also be effective against enterobiasis. Albendazole thus appears to be a useful anti-helminthic in enterobiasis patients in whom Pyrantel Pamoate is not effective. This is, to our knowledge, the first case of enterobiasis treated with albendazole in Japan.
Plasma pharmacokinetics, faecal excretion and efficacy of pyrantel pamoate paste and granule formulations following per os administration in donkeys naturally infected with intestinal strongylidae.[Pubmed:25015542]
Vet Parasitol. 2014 Sep 15;205(1-2):186-92.
The plasma disposition, faecal excretion and efficacy of two formulations of Pyrantel Pamoate in donkeys were examined in a controlled trial. Three groups of seven donkeys received either no medication (control) or pyrantel paste or granule formulations at horse dosage of 20mg/kg B.W. (equals 6.94 mg/kg PYR base) of body weight. Heparinized blood and faecal samples were collected at various times between 1 and 144 h after treatment. The samples were analysed by high-performance liquid chromatography. The last detectable plasma concentration (tmax) of paste formulation was significantly earlier (36.00 h) compared with granule formulation (46.29 h). Although, there was no significant difference on terminal half lives (t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00) and MRT (24.80 h vs. 25.44 h) values; the Cmax (0.09 mug/ml) AUC (2.65 mugh/ml) values of paste formulation were significantly lower and smaller compared with those of granule formulation (0.21 mug/ml and 5.60 mugh/ml), respectively. The highest dry faecal concentrations were 710.46 mug/g and 537.21 mug/g and were determined at 48 h for both paste and granule formulation of PYR in donkeys, respectively. Pre-treatment EPG of 1104, 1061 and 1139 were observed for the control, PYR paste and PYR granule groups, respectively. Pre-treatment EPG were not significantly different (P>0.1) between groups. Post-treatment EPG for both PYR treatment groups were significantly different (P<0.001) from the control group until day 35. Following treatments the PYR formulations were efficient (>95% efficacy) until day 28. In all studied donkeys, coprocultures performed at day-3 revealed the presence of Cyathostomes, S. vulgaris. Faecal cultures performed on different days from C-group confirmed the presence of the same genera. Coprocultures from treated animals revealed the presence of few larvae of Cyathostomes.
Massive proteinuria: a possible side effect of pyrantel pamoate?[Pubmed:21500989]
Ren Fail. 2011;33(5):534-6.
Drug-induced renal injury represents a frequent clinical entity. The most common drugs associated with acute tubular necrosis are aminoglycosides, amphotericin B, radiocontrast agents, and cyclosporine, but no data exist about the potential renal toxicity due to anthelmintics administration. Anthelmintics are commonly considered quite safe agents, and side effects such as gastrointestinal, neurologic, hematologic, or hepatic injury have been only rarely described. We report a 4-year-old boy with persistent massive proteinuria without any other symptoms/signs suggesting nephrotic syndrome (NS). The only relevant anamnestic data was the administration of Pyrantel Pamoate due to oxyuriasis 7 days before the proteinuria development. The patient was affected by NS diagnosed 6 months before and treated with a 12-week course of corticosteroids. During follow-up, carried out at 3 and 6 months after discharge, he did not show further episodes of proteinuria, and no clinical symptoms/signs suggesting a relapse of NS were ever detected. Considering that the proteinuria observed in our patient spontaneously disappeared after 10 days without any treatment, apart from the interruption of the anthelmintic therapy, we would like to alert pediatricians about the possible occurrence of anthelmintics-related renal complications especially among predisposed patients and to perform a watchful waiting not considering the presence of even massive proteinuria as a certain sign of NS relapse.
Chemometric quality inspection control of pyrantel pamoate, febantel and praziquantel in veterinary tablets by mid infrared spectroscopy.[Pubmed:24566119]
Spectrochim Acta A Mol Biomol Spectrosc. 2014 May 5;125:396-403.
This paper describes the development and validation of a new multivariate calibration method based on diffuse reflectance mid infrared spectroscopy for direct and simultaneous determination of three veterinary pharmaceutical drugs, Pyrantel Pamoate, praziquantel and febantel, in commercial tablets. The best synergy interval partial least squares (siPLS) model was obtained by selecting three spectral regions, 3715-3150, 2865-2583, and 2298-1733 cm(-1), preprocessed by first derivative and Savitzky-Golay smoothing followed by mean centering. This model was built with five latent variables and provided root mean square errors of prediction (RMSEP) equal or lower than 0.69 mg per 100 mg of powder for the three analytes. The method was validated according the appropriate regulations through the estimate of figures of merit, such as trueness, precision, linearity, analytical sensitivity, bias and residual prediction deviation (RPD). Then, it was applied to three different veterinary pharmaceutical formulations found in the Brazilian market, in a situation of multi-product calibration, since the excipient composition of these commercial products, which was not known a priori, was modeled by an experimental design that scanned the likely content range of the possible constituents. The results were verified with high performance liquid chromatography with diode array detection (HPLC-DAD) and high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and were in agreement with the predicted values at 95% confidence level. The developed method presented the advantages of being simple, rapid, solvent free, and about ten times faster than the HPLC ones.
